Search Immortality Topics:

Page 22«..10..21222324..3040..»


Category Archives: Neurology

Woman has four-year wait to see Northern Ireland neurologist – The Guardian

A single mother of six children has been waiting four years and four months to see a consultant for suspected multiple sclerosis in Northern Ireland as officials admit in leaked court papers that health waiting lists have spiralled out of control.

Although referred to a neurologist in June 2017, Eileen Wilson, 47, has still not received a date to see the specialist despite suffering choking episodes that leave her blue in the face, loss of muscle control and a multitude of other symptoms.

She is one of the hundreds of thousands of patients suffering in silence because of the chronic waiting lists that have been building since 2013, according to testimony submitted to the high court.

Her case is at the centre of two landmark cases to be heard in December and January against the Northern Ireland health minister, Robin Swann, the UK chancellor, Rishi Sunak, and the health secretary, Savid Javid, who were named as defendants in the case last week after affidavits from Northern Irelands Department of Health blamed years of underfunding for the crisis.

Sitting in her garden in her army veteran house in Belfast, Wilson said she would not give up the fight even though the human rights commission, her GP, and her MP, Gavin Robinson, have all failed to get her an appointment.

I just want to know whats wrong with me, she says.

She explains how she staggers around her home like a drunk even though she does not drink and now suffers episodes of sleep paralysis, which has been likened to locked-in syndrome.

When I go to bed all the worry is there, its like a washing machine on full spin, she said.

I worry that if I fall or choke, thats going to be the end of it. Die? Yes, she answers. It can happen anytime. Its like something is stuck in my throat. Ive gone blue in the face. It lasts for a few minutes but it feels like hours, she said.

To her shock, she heard through her MP that her GPs referral had been downgraded from urgent to routine, with the chief executive of South Eastern health and social care trust telling Robinson that regrettably the waiting time for an appointment was 163 weeks three years and 13 weeks.

I am very sorry that we have not yet been able to offer Mrs Wilson an appointment, he said.

Four years and four months later, she is none the wiser.

Her solicitor, Ciaran OHare of McIvor Farrell, has already applied successfully for leave for a judicial review, which is now listed for January with a second case expedited for hearing in December over a failed bid to get her an appointment overseas under EU legislation transposed into domestic law.

He said her case was for the benefit of the people of Northern Ireland and is asking the court to conclude that the waiting lists, the worst in the UK for much of the past decade, are unlawful and a breach of human rights.

This saga has been going on in Northern Ireland for over 10 years and hospital waiting lists have been getting longer and longer. We do not have the NHS here, like in England; we have health and social care and it doesnt work, said OHare.

This is the first case of its kind and it is absolutely crucial because something must be done to end the suffering that is occurring every single day with people languishing and dying on hospital waiting lists, he added.

Recent figures show nearly a fifth of Northern Irelands population are waiting for a first appointment and more than half of those are waiting for more than a year.

It is the case that the majority of people on the waiting list are waiting for more than a year, which is pretty extraordinary, said Mark Dayan, a policy analyst at the health services thinktank the Nuffield Trust.

Waiting lists are the worst in the UK and possibly in Europe. Last week, the childrens commissioner revealed that 24 children with confirmed or suspected cancer were among the 17,000 minors waiting more than a year to see a specialist.

Affidavits submitted to the courts and seen by the Guardian paint a grim picture.

A senior official in the Department of Health in his testimony, said the delays were extremely regrettable but the health minister had repeatedly said a significant increase in funding was necessary to make a return to acceptable levels.

While doctors, nurses, other health professionals and managers have made every effort to ensure that any negative impact on patients has been kept to a minimum, waiting times have continued to grow to a level where many believe that they are now out of control, he added.

Dayan said Northern Irelands waiting lists began to spiral to more and more unacceptably poor levels relative to the rest of the UK 10 years ago.

He said one year-plus waits were almost unheard of in England before Covid, but have been common in Northern Ireland. Out of an estimated 460,000 on a waiting list, 250,000 have been on it for more than a year, he said.

The Department of Health declined to comment due to ongoing court proceedings.

See the article here:
Woman has four-year wait to see Northern Ireland neurologist - The Guardian

Posted in Neurology | Comments Off on Woman has four-year wait to see Northern Ireland neurologist – The Guardian

Global Neurology Devices Market 2021: SWOT Analysis of Key Driving Factors for Growing CAGR Value | Top Brands: Boston Scientific, Terumo Corporation,…

The latest research report on the Global Neurology Devices Market provides the cumulative study on the COVID-19 outbreak to provide the latest information on the key features of the Neurology Devices market. This intelligence report contains investigations based on current scenarios, historical records and future forecasts. The report contains various market forecasts related to market size, revenue, production, CAGR, consumption, gross margin in the form of charts, graphs, pie charts, tables and more. While emphasizing the main driving and restraining forces in this market, the report also offers a comprehensive study of future trends and developments in the market. It also examines the role of the major market players involved in the industry, including their business overview, financial summary and SWOT analysis. It provides a 360-degree overview of the industries competitive landscape. Neurology Devices Market shows steady growth and CAGR is expected to improve during the forecast period.

The Global Neurology Devices Market Report gives you in-depth information, industry knowledge, market forecast and analysis. The global Neurology Devices industry report also clarifies financial risks and environmental compliance. The Global Neurology Devices Market Report helps industry enthusiasts including investors and decision makers to make reliable capital investments, develop strategies, optimize their business portfolio, succeed in innovation and work safely and sustainably.

Get FREE Sample copy of this Report with Graphs and Charts at:https://reportsglobe.com/download-sample/?rid=131493

Top Key Players Profiled in this report are:

The report is an assortment of direct information, subjective and quantitative assessment by industry specialists, contributions from industry examiners and Neurology Devices industry members over the worth chain. The report offers a top to bottom investigation of parent market patterns, macroeconomic measures, and control components. Besides, the report likewise overviews the subjective effect of unmistakable market factors on Neurology Devices market sections and geologies.

Neurology Devices Market Segmentation:

Based on Type

Based on Application

Global Neurology Devices Market: Regional Segments

The different section on regional segmentation gives the regional aspects of the worldwide Neurology Devices market. This chapter describes the regulatory structure that is likely to impact the complete market. It highlights the political landscape in the market and predicts its influence on the Neurology Devices market globally.

Get up to 50% discount on this report at:https://reportsglobe.com/ask-for-discount/?rid=131493

The Study Objectives are:

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neurology Devices market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Some Major Points from Table of Contents:

Chapter 1. Research Methodology & Data Sources

Chapter 2. Executive Summary

Chapter 3. Neurology Devices Market: Industry Analysis

Chapter 4. Neurology Devices Market: Product Insights

Chapter 5. Neurology Devices Market: Application Insights

Chapter 6. Neurology Devices Market: Regional Insights

Chapter 7. Neurology Devices Market: Competitive Landscape

Ask your queries regarding customization at: https://reportsglobe.com/need-customization/?rid=131493

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

See the original post:
Global Neurology Devices Market 2021: SWOT Analysis of Key Driving Factors for Growing CAGR Value | Top Brands: Boston Scientific, Terumo Corporation,...

Posted in Neurology | Comments Off on Global Neurology Devices Market 2021: SWOT Analysis of Key Driving Factors for Growing CAGR Value | Top Brands: Boston Scientific, Terumo Corporation,…

Retired neurologist with Alzheimer’s knows firsthand the risks of Aduhelm – STAT – STAT

Daniel Gibbs had received only four monthly doses of Biogens experimental Alzheimers drug in a clinical trial in 2017 when he ended up in an intensive care unit.He had an excruciating headache, and his blood pressure was so high that doctors thought he might be having a stroke.

It turned out that the retired Portland, Ore., neurologist who had treated Alzheimers patients before he was diagnosed with the disease himself in 2015 was experiencing some of the worst reported side effects of the drug. Doctors prescribed medicines to lower his blood pressure, which reached 206/116, and later to reduce brain swelling. But for weeks afterward, he struggled to read, follow conversations, and do simple math. He recovered but never again took the Alzheimers drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Continued here:
Retired neurologist with Alzheimer's knows firsthand the risks of Aduhelm - STAT - STAT

Posted in Neurology | Comments Off on Retired neurologist with Alzheimer’s knows firsthand the risks of Aduhelm – STAT – STAT

Ocala neurologist to pay $800K to settle allegations of prescribing unnecessary drugs – Ocala

A lawsuit filed against the Florida Neurological Center, LLC and its owner, Dr. Lance Kim of Ocala, in which the defendants were accused of several fraudulent practices under the False Claims Act, has been partially settled.

Kim and the Florida Neurological Center (FNC), located at 2237 SW 19th Ave. Road, Suite 101, have agreed to pay $800,000 to resolve allegations that Kim prescribed medically unnecessary and unreasonable prescription drugs, according to a press release from the U.S. Attorneys Office for the Middle District of Florida.

The release specifically noted Acthar Gel, a prescription drug that cost the Medicare program around $35,000 for every five-day supply Kim prescribed.

$65 million expansion: Ocala Regional Medical Center celebrates groundbreaking of neuro ICU, CV suites

COVID-19 spike: Marion County's 7-day positivity rate now above 19 percent, CDC says

Things you didn't know about WEC: Secret garden, saddle stools, Journey's keyboardist

The agreement partially resolves the allegations brought against Kim and the center, andthere has been no determination of liability.

The lawsuit was filed in Orlando by Michael Singbush, Andrea Herrera and Harvey Kessler MeyerIV, all former employees of the Florida Neurological Center between 2014 and 2017. Under the False Claims Act, private individuals, or relators, can sue, on behalf of the government, companies and individuals that they believe to be defrauding government programs.

Also under the act, the relators are permitted to receive a share of the recovery, totaling $144,000 in this case.

Florida Attorney General Ashley Moodys office issued a press release on the settlement Tuesday, stating that she is working with federal partners to recover thousands of dollars for Floridas Medicaid program related to the settlement.

The program will receive over $113,000 in restitution from the agreement.

Defrauding Floridas Medicaid program is not a victimless crime, Moody said in the release. It harms the taxpayers of our great state. My Medicaid Fraud Control Unit investigators work hard to protect taxpayers by identifying, investigating and stopping fraud exploiting this taxpayer-funded health care program and recovering lost funds whenever possible.

FNC has served Marion County since 1998, according to its website. It specializes in evaluating and treating neurological disorders such as Alzheimers disease, neuropathy, muscle disorders and sleep disorders.

Kim received his undergraduate degree in biochemistry from Boston University and medical degree from Nova Southeastern University in Fort Lauderdale.

He has worked as a research fellow at the Harvard Medical School/Massachusetts General Hospital, interned in internal medicine at Northwestern University Medical Center and received a residency and fellowship in neurology from the University of Chicago.

Kim is the owner and sole practicing physician of FNC.

In a pretrial statement from May, the plaintiffs had maintained that Kim and FNC violated the False Claims Act (FCA) and that each plaintiff faced retaliation after complaining of the illegal actions.

The relators explained that the basic requirement for reimbursement from Medicare, Medicaid and other government healthcare programs is that services are reasonable and medically necessary. They described various ways in which they believed FNC submitted false claims.

The defendants denied any wrongdoing under the FCA, and the parties agreed to a voluntary dismissal of most of the counts on Tuesday.

The claimsthat each relator faced retaliation for questioning the practices and was either forced to resign or fired are still pending.

FNC and Kim deny any retaliation or that the relators engaged in protected activity, which prevents whistleblowers from retaliation.

FNC also soughtdamagein a counterclaim against Singbush, Herrera and Meyer, alleging unlawful use and disclosure of confidential information about patients, as well as breach of employment agreements. Those claims were dismissed in June.

The U.S. Attorneys Office for the Middle District of Florida reminds that tips about potential fraud, waste, abuse and mismanagement can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).

Contact reporter Danielle Johnson at djohnson@gannett.com.

Read the rest here:
Ocala neurologist to pay $800K to settle allegations of prescribing unnecessary drugs - Ocala

Posted in Neurology | Comments Off on Ocala neurologist to pay $800K to settle allegations of prescribing unnecessary drugs – Ocala

Oyesiku to Receive Distinguished Service Award from Society of University Neurosurgeons | Newsroom – UNC Health and UNC School of Medicine

The award will presented to Dr. Oyesiku at the Societys 2021 Annual Meeting August 8-11.

Nelson M. Oyesiku, MD, PhD, FACS, Chair Chair of the UNC School of Medicine Department of Neurosurgery, will receive the Distinguished Service Award given by the Society of University Neurosurgeons at their 2021 Annual Meeting in Whitefish, Montana, August 8-11.

Prior to joining the UNC faculty on April 1, 2021, Dr. Oyesiku was Professor of Neurological Surgery and Medicine (Endocrinology) at Emory University, Atlanta, Georgia and the Inaugural Daniel Louis Barrow Chair in Neurosurgery, Vice-Chairman of the Department of Neurological Surgery and Director of the Neurosurgical Residency Program. Dr. Oyesikus clinical expertise is pituitary medicine and surgery. Dr. Oyesiku was co-director of the Emory Pituitary Center and has developed one of the largest practices entirely devoted to the care of patients with pituitary tumors in the country and has performed over 3,700 pituitary tumor operations. Dr. Oyesiku obtained his MD from the University of Ibadan, Nigeria. He obtained an MSc in Occupational Medicine from the University of London, UK and completed a PhD in Neuroscience at Emory University. He completed his Surgery Internship at the University of Connecticut-Hartford Hospital and obtained his neurosurgical training at Emory University, Atlanta. He is board-certified by the American Board of Neurological Surgery. He received an NIH K08 Award and Faculty Development Award from the Robert Wood Johnson Foundation was a recipient of an NIH R01 award and PI of the NIH/NINDS R25 Research Education Program for Residents and Fellows in Neurosurgery. Dr. Oyesiku has served on several NIH Study Sections. Dr. Oyesikus research is focused on the molecular pathogenesis of pituitary adenomas, and tumor receptor imaging and targeting for therapy.

Dr. Oyesiku has served on various state, regional, national and international committees for all the major neurosurgical organizations. He has served on the Board of Directors and as Chairman of the American Board of Neurological Surgery. He was on the ACGME-Residency Review Committee of Neurosurgery. He is a Fellow of the American College of Surgeons and has served on its Board of Governors. Dr. Oyesiku has been President of the Congress of Neurological Surgeons. He has served as Secretary/Treasurer and President of the Georgia Neurosurgical Society, President of the Society of University Neurosurgeons, and Vice-President of the American Academy of Neurological Surgeons. He is President of the International Society of Pituitary Surgeons. He is President-Elect of the World Federation of Neurological Surgeons.

Dr. Oyesiku is Editor-in-Chief of NEUROSURGERY, OPERATIVE NEUROSURGERY and NEUROSURGERY OPEN leading journals in neurosurgery. He is author of over 180 scientific articles and book chapters.

He has been selected by his peers as one of The Best Doctors in America and was selected by the Consumer Research Council of America as one of Americas Top Surgeons. He is named in Marquis Whos Who in America. He is a member of the Honor Medical Society Alpha Omega Alpha. He was awarded the Gentle Giant Award by the Pituitary Network Association for his services to Pituitary Surgery and Medicine. He is on the Medical Advisory Board of the Cushings Support and Research Foundation. He has been visiting professor and invited faculty at several departments of neurosurgery in the United States and abroad.

Read more from the original source:
Oyesiku to Receive Distinguished Service Award from Society of University Neurosurgeons | Newsroom - UNC Health and UNC School of Medicine

Posted in Neurology | Comments Off on Oyesiku to Receive Distinguished Service Award from Society of University Neurosurgeons | Newsroom – UNC Health and UNC School of Medicine

Delays in thrombolysis during COVID-19 are associated with worse neurological outcomes: the Society of Vascular and Interventional Neurology…

This article was originally published here

J Neurol. 2021 Jul 31. doi: 10.1007/s00415-021-10734-z. Online ahead of print.

ABSTRACT

INTRODUCTION: We have demonstrated in a multicenter cohort that the COVID-19 pandemic has led to a delay in intravenous thrombolysis (IVT) among stroke patients. Whether this delay contributes to meaningful short-term outcome differences in these patients warranted further exploration.

METHODS: We conducted a nested observational cohort study of adult acute ischemic stroke patients receiving IVT from 9 comprehensive stroke centers across 7 U.S states. Patients admitted prior to the COVID-19 pandemic (1/1/2019-02/29/2020) were compared to patients admitted during the early pandemic (3/1/2020-7/31/2020). Multivariable logistic regression was used to estimate the effect of IVT delay on discharge to hospice or death, with treatment delay on admission during COVID-19 included as an interaction term.

RESULTS: Of the 676 thrombolysed patients, the median age was 70 (IQR 58-81) years, 313 were female (46.3%), and the median NIHSS was 8 (IQR 4-16). Longer treatment delays were observed during COVID-19 (median 46 vs 38 min, p = 0.01) and were associated with higher in-hospital death/hospice discharge irrespective of admission period (OR per hour 1.08, 95% CI 1.01-1.17, p = 0.03). This effect was strengthened after multivariable adjustment (aOR 1.15, 95% CI 1.07-1.24, p < 0.001). There was no interaction of treatment delay on admission during COVID-19 (pinteraction = 0.65). Every one-hour delay in IVT was also associated with 7% lower odds of being discharged to home or acute inpatient rehabilitation facility (aOR 0.93, 95% CI 0.89-0.97, p < 0.001).

CONCLUSION: Treatment delays observed during the COVID-19 pandemic led to greater early mortality and hospice care, with a lower probability of discharge to home/rehabilitation facility. There was no effect modification of treatment delay on admission during the pandemic, indicating that treatment delay at any time contributes similarly to these short-term outcomes.

PMID:34333701 | DOI:10.1007/s00415-021-10734-z

Read more here:
Delays in thrombolysis during COVID-19 are associated with worse neurological outcomes: the Society of Vascular and Interventional Neurology...

Posted in Neurology | Comments Off on Delays in thrombolysis during COVID-19 are associated with worse neurological outcomes: the Society of Vascular and Interventional Neurology…